A few hours ago, fiscal and public health safety and sanity prevailed when the Food and Drug Administration clarified an order on February 3 approving the drug Makena, which is an injectable medication for women at risk of preterm birth, one of the biggest health care challenges that our country faces. There are a half million premature births in this country. They cost the health care system $29 billion. They are the leading cause of infant mortality. This new medication which the FDA approved on February 3 is promising, but it costs $1,500 per injection, $30,000 per pregnancy. At the same time, OB-GYNs in this country have been prescribing a compound alternative that costs only $20 per treatment per medication. And yet the order on February 3 indicated that there would only be exclusive treatments under the $1,500 medication. The order this morning clarifies that there will be no exclusivity, that OB-GYNs will continue to be able to prescribe the cheaper alternative, but FDA retains its power to still require exclusivity. For the sake of taxpayers and patients, Congress must keep a close eye on the FDA to not take away this option to OB-GYNs all across America. ____________________
On the recordMarch 30, 2011
Share
More from Joe Courtney
Sep 22, 2025
The Interior Department should take the hint and let the thousands of construction workers finish the job.
Feb 24, 2025
We are now in the eighth week of the 119th Congress, which has distinguished itself with incredibly low productivity and low effort. So far, we have brought up just a bunch of moldy old leftovers from the last Congress. We have been…
Sep 9, 2024
the reason, and as a former employer, is that if Congress made that move, it basically would add to the taxable income of all the employees
Sep 9, 2025
this is documentary proof that the concern that is being raised with this amendment is something that is already part of the permitting process. The Bureau of Ocean Energy Management signed off on the project. Again, we are about $4…





